Dapagliflozin is an oral hypoglycemic agent belonging to the class of sodium-glucose cotransporter 2 (SGLT2) inhibitors. It works by inhibiting the SGLT2 in the kidneys, reducing the renal reabsorption of glucose, and increasing the excretion of glucose in urine, thereby exerting its hypoglycemic effect.
I. Basic Information
English Name: Dapagliflozin
Molecular Formula: C21H25ClO6
Molecular Weight: 408.88
CAS Number: 461432-26-8
II. Indications
Indications: Suitable for patients with type 2 diabetes whose condition is not effectively controlled by diet and exercise. It can be used as monotherapy or in combination with other oral hypoglycemic agents or insulin.
III. Primary Efficacy
Blood Glucose Control: Reduces blood glucose levels, particularly fasting and postprandial glucose, by promoting glucose excretion.
Weight Loss: Aids in weight reduction, especially abdominal fat, by excreting excess glucose through urine.
Reduced Hypertension Risk: Lowers blood pressure through fluid reduction and vasodilatation.
Renal Protection: Decreases the leakage of urinary albumin, slowing the progression of diabetic nephropathy.
